JP2004315405A - Constipation ameliorant - Google Patents

Constipation ameliorant Download PDF

Info

Publication number
JP2004315405A
JP2004315405A JP2003109959A JP2003109959A JP2004315405A JP 2004315405 A JP2004315405 A JP 2004315405A JP 2003109959 A JP2003109959 A JP 2003109959A JP 2003109959 A JP2003109959 A JP 2003109959A JP 2004315405 A JP2004315405 A JP 2004315405A
Authority
JP
Japan
Prior art keywords
starch
intestinal
constipation
foods
hydroxypropylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003109959A
Other languages
Japanese (ja)
Other versions
JP4463494B2 (en
Inventor
Rei Shimotoyotome
玲 下豊留
Noriyuki Yajima
則幸 谷島
Naoki Yamamoto
尚基 山本
Takatoshi Murase
孝利 村瀬
Ichiro Tokimitsu
一郎 時光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2003109959A priority Critical patent/JP4463494B2/en
Publication of JP2004315405A publication Critical patent/JP2004315405A/en
Application granted granted Critical
Publication of JP4463494B2 publication Critical patent/JP4463494B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a material such as a food, a medicine which exhibits ameliorating effect on constipation, intestinal environment, and the like, is highly safe, has a wide application range and does not impair palatability. <P>SOLUTION: This constipation ameliorant as an intestinal ameliorant, an intestinal tract mucus production promoter and an intestinal short-chain fatty acid production promoter comprise a hydroxypropylated starch as an active ingredient. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は、便秘の改善、腸内環境の改善及び腸管粘液の産生促進作用等を有し、食品又は医薬品として有用な素材に関する。
【0002】
【従来の技術及び発明が解決しようとする課題】
近年、食習慣の変化や、ストレス、薬物、胃、腸、肝障害等によって、腸内のpHがアルカリ領域へ移行する傾向がある。このように腸内環境がアルカリ性に傾くと、ウエルシュ菌、大腸菌、腸球菌等の繁殖が活発化し、腸内腐敗、細菌による毒素や発癌性物質の産生等が起こるとされている。
また、食物繊維の摂取不足から、現代人の多くは便秘を経験することが多く、便秘を危険因子とする結腸癌、直腸癌もまた増加している。
従って、このような社会的背景から、便秘対策や腸内環境改善は極めて重要である。
【0003】
従来、便秘の改善や腸内環境の改善には、ビフィズス菌や乳酸菌等の有用菌を摂取したり、高食物繊維食の摂取が推奨されている。例えば、便秘の予防・改善に関連する食品素材としては、小麦ふすまに代表される水不溶性食物繊維、難消化性デキストリンに代表される水溶性食物繊維、高アミロースコーン澱粉等の消化抵抗性澱粉が挙げられ、糞便排泄量や回数、及び糞便の含水率を増大することにより軟便化する等の効果が知られている(例えば、非特許文献1〜4参照)。
【0004】
しかしながら、従来の水不溶性食物繊維、水溶性食物繊維、消化抵抗性澱粉等の食品素材が上記の生理作用を発現するには、高用量かつ長期間摂取し続けなければならない。更にそれらを用いて飲食品を製造した場合、飲食品本来の持つ外観、味、歯触り、滑らかさ等の食感を損う場合が多いため、食品中に十分な量で含有させることが困難であり、適用分野が限定されたり、更にそのような飲食品を長期間摂取し続けるのが困難という問題があった。
【0005】
ヒドロキシプロピル化された澱粉は、透明性が高くフィルム形成性に優れ、低温保存安定性、凍結・解凍安定性の高い性質を持つことが知られており、米国ではFDAで食品への使用が許可されている(例えば、非特許文献3参照)。
しかしながら、ヒドロキプロピル化された澱粉類に、便秘改善作用や腸内環境の改善作用があることはこれまでに知られていない。
【0006】
本発明は、便秘や腸内環境等を改善する効果を発揮し、安全性が高いと共に適用範囲が広く、且つ食感を損なうことが少ない食品、医薬品等の素材を提供することを目的とする。
【0007】
【非特許文献1】
Am J Gastroentero 1 1987 82(12):1259−63
【非特許文献2】
健康・栄養食品研究 1999 Vol.2 No.1 p44
【非特許文献3】
Am J Clin Nutr 1995 62(1):121−30
【非特許文献4】
日本家政学会誌 1998 49(9): 985−992
【0008】
【課題を解決するための手段】
本発明者らは、従来の難消化性澱粉やセルロース、難消化性デキストリンに代表される食物繊維とは異なる物性を有し、便秘や腸内環境改善に有効な素材を探索した結果、ヒドロキシプロピル化された澱粉が、僅かな摂取量で、糞便の量やその含水率を増加させ、腸管内の短鎖脂肪酸を増加させて腸内pHを低下させると共に、腸管内のムチンの発現量を増加させる作用を有し、便秘や腸内環境の改善等に効果を発揮する食品、医薬品素材として有用であることを見出した。
【0009】
すなわち、本発明は、ヒドロキシプロピル化された澱粉を有効成分とする便秘改善剤、腸内環境改善剤、腸管粘液産生促進剤及び腸内短鎖脂肪酸産生促進剤を提供するものである。
【0010】
【発明の実施の形態】
本発明のヒドロキシプロピル化された澱粉は、澱粉又は加工澱粉を通常の方法によりヒドロキシプロピル化することにより得ることができる。具体的にはプロピレンオキサイドを澱粉に反応させることにより得ることができる。
また、ナショナルフリジェックス(タピオカ由来、ナショナルスターチアンドケミカル社)、ナショナル1658(コーン由来、ナショナルスターチアンドケミカル社)、サームフロー(ワキシーコーン由来、ナショナルスターチアンドケミカル社)、サームテックス(ワキシーコーン由来、ナショナルスターチアンドケミカル社)等の市販品を用いることもできる。
【0011】
原料澱粉としては、例えばワキシーコーン澱粉、コーン澱粉、小麦澱粉、米澱粉、糯米澱粉、馬鈴薯澱粉、甘露澱粉、タピオカ澱粉、サゴ澱粉等が挙げられるが、アミロペクチン含量が70重量%以上、好ましくは75〜100%、更に好ましくは90〜100%であるものが、糊液の透明性が高く、飲食品に応用した場合にその外観を損わず、適用範囲が広くなることより好ましい。中でも、原料澱粉としては、ワキシーコーン澱粉、タピオカ澱粉が好ましい。
【0012】
本発明における「ヒドロキシプロピル化された澱粉」には、他の加工処理を組み合わせることにより得られるヒドロキシプロピル化された澱粉も含まれる。組み合わせることのできる加工処理としては酢酸、オクテニルコハク酸、リン酸等のエステル化処理やヒドロキシプロピル化以外のカルボキシメチルエーテル化等によるエーテル化処理、トリメタリン酸塩、ヘキサメタリン酸塩、オキシ塩化リン、アジピン酸、エピクロルヒドリン等、常用の架橋剤を用いた架橋化処理、酸化処理、酸処理、漂白処理、湿熱処理、熱処理、酵素処理等が挙げられ、その内1種又は2種以上の加工を組み合わせても良い。中でも、エステル化処理が好ましく、リン酸化処理、特にリン酸架橋処理が好ましい。リン酸化処理の程度としては、結合リン含量が0.0001〜2%の範囲が挙げられるが、好ましくは0.0001〜0.5%、更に好ましくは0.0001〜0.2%であるものが食感等の面から好ましい。
【0013】
ヒドロキシプロピル化の程度としては、置換度(澱粉中の無水グルコース1残基当たりのヒドロキシプロピル基の数)が0.001〜1であるのが好ましく、より好ましくは0.05〜0.5であり、更に0.1〜0.3であるのが好ましい。
【0014】
上記ヒドロキシプロピル化された澱粉は、澱粉から簡単な工程で、高純度で比較的安価に製造できる。また安全性が高く、従来の食物繊維や難消化性澱粉と比較して、各種飲食品、医薬品、ペットフード等に用いたときの違和感がない。また、耐冷凍性に優れているので、解凍による変質が起こりにくいという利点を有し得る。
【0015】
そして、ヒドロキシプロピル化された澱粉は、後記実施例に示すように、第1に、糞便の量やその含水率を増加させ、軟便化させる作用を有することから、便秘を危険因子とする結腸癌や直腸癌の予防等の効果を発揮する。第2に、腸管内の短鎖脂肪酸を増加させ、腸内pHを低下させる作用を有することから、腸内環境の悪化に起因する結腸癌や直腸癌を予防したり、カルシウム吸収を促進する等の効果を発揮する。第3に腸管内のムチンの発現量を増加させる作用を有することから、粘液により腸管粘膜が保護され、大腸炎及び結腸癌や直腸癌の予防等の効果を発揮し得る。
従って、本発明のヒドロキシプロピル化された澱粉は、便秘改善剤、腸内環境改善剤、腸管粘液産生促進剤、腸内短鎖脂肪酸産生促進剤(以下、便秘改善剤等という)として、ヒト若しくは動物用の食品又は医薬品の素材となり得る。
【0016】
本発明の便秘改善剤等は、ヒドロキシプロピル化澱粉の一種以上を単体でヒト及び動物に投与できる他、各種飲食品、医薬品、ペットフード等に配合して摂取することができる。食品としては、便秘の改善、腸内環境改善、Ca吸収促進、消化管粘膜保護等の生理機能をコンセプトとする美容食品、病者用食品、特定保健用食品に応用できる。医薬品として使用する場合は、例えば、錠剤、顆粒剤等の経口用固形製剤や、内服液剤、シロップ剤等の経口用液体製剤とすることができる。
尚、経口用固形製剤を調製する場合には、本発明のヒドロキシプロピル化澱粉に賦形剤、必要に応じて結合剤、崩壊剤、滑沢剤、着色剤、矯味剤、矯臭剤等を加えた後、常法により錠剤、被覆錠剤、顆粒剤、散剤、カプセル剤等を製造することができる。また、経口用液体製剤を調製する場合は、矯味剤、緩衝剤、安定化剤、矯味剤等を加えて常法により内服液剤、シロップ剤、エリキシル剤等を製造することができる。
【0017】
上記各製剤中に配合されるべきヒドロキシプロピル化された澱粉の配合量は、通常5〜100重量%、好ましくは20〜100重量%、更に好ましくは30〜100重量%とするのが好ましい。
【0018】
本発明の便秘改善剤等の投与量(有効摂取量)は、一日当り0.01g/kg体重以上とするのが好ましく、特に0.1g/kg体重以上、更に0.4g/kg体重以上とするのが好ましい。
【0019】
【実施例】
【0020】
試験例1 便秘改善作用・腸内環境改善作用・腸管粘液産生促進作用
コーン澱粉は、ナショナルスターチアンドケミカル社から入手した。ヒドロキシプロピル化された澱粉として、一般に市販されているナショナル1658(コーン由来、ナショナルスターチアンドケミカル社)、サームフロー(ワキシーコーン由来、ナショナルスターチアンドケミカル社)、及び上記コーン澱粉をJ Nutr 1998 128(5):848−54に記載の方法でヒドロキシプロピル化したものを用いた。
【0021】
SDラット(雄、8週令)を1群5匹とし、各種澱粉を用いて、表1に示す配合で調製した食餌を用いて1週間飼育した。この間毎日、糞便の乾燥重量と含水率を測定した。飼育後、ラットを屠殺し、盲腸内容物のpH、及び短鎖脂肪酸量(酢酸、プロピオン酸、酪酸の総量)を測定した。更にラット結腸を摘出し、ノーザンブロット法により、ムチン遺伝子(MUC3)の発現を定量した。
尚、pHは盲腸内容物を蒸留水で2倍希釈後、pHメーターにて測定し、短鎖脂肪酸は盲腸内容物を0.05N HSOで10倍希釈後、HPLC(溶離液:0.12N硫酸カラム:IC sep TCE−10N 300(トンラスジェノジック社)、流速0.4mL/分で定量した。
ラットの糞便排泄量、平均糞便含水率、盲腸内pH、盲腸内短鎖脂肪酸量、ムチン発現量(コーン澱粉を100とした場合の相対量)を表2に示す。
【0022】
【表1】

Figure 2004315405
【0023】
【表2】
Figure 2004315405
【0024】
表2の結果から、ヒドロキシプロピル化された澱粉(コーン、ワキシーコーン由来)を5%配合した飼料を摂取したラットでは、原料澱粉(コーン澱粉)を配合した飼料を摂取したマウスに比較して、糞便量が多く、糞便含水率が高く、便秘改善効果が認められることがわかる。また盲腸内短鎖脂肪酸濃度が高いことから、盲腸内pHが低くなっており、腸内環境改善効果が認められることがわかる。更にムチン(MUC3)発現量も多く、腸管粘液産生促進効果が認められることがわかる。
【0025】
【発明の効果】
本発明の便秘改善剤等は、便秘の改善、腸内短鎖脂肪酸の産生促進、腸内pH等の腸内環境の改善及び腸管粘液産生促進効果を発揮し、食品、医薬品等として有用である。特に、有効成分であるヒドロキシプロピル化澱粉又はその誘導体は、澱粉を原料とすることから人体に対する安全性に優れ、また糊化しやすいので、飲食品への適用範囲が広く、パン、麺類、焼き菓子(ケーキ、クッキー等)、ゼリー類、飲料等に配合した場合、それらが本来持つ食感を損なうことが少ない。また耐凍結性に優れ、解凍しても変質しにくいことから、各種飲食品として使用する場合にその有用性が高い。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a material having an effect of improving constipation, improving the intestinal environment, promoting intestinal mucus production, and the like, and being useful as a food or pharmaceutical.
[0002]
Problems to be solved by the prior art and the invention
In recent years, the pH in the intestine tends to shift to an alkaline region due to changes in eating habits, stress, drugs, stomach, intestines, liver disorders and the like. It is said that when the intestinal environment becomes alkaline, proliferation of Welsh bacteria, Escherichia coli, enterococci and the like is activated, and intestinal spoilage, production of toxins and carcinogenic substances by bacteria and the like are caused.
In addition, many modern people often experience constipation due to inadequate dietary fiber intake, and colon and rectal cancers with constipation as a risk factor are also increasing.
Therefore, from such a social background, countermeasures for constipation and improvement of the intestinal environment are extremely important.
[0003]
Conventionally, to improve constipation and the intestinal environment, it has been recommended to ingest useful bacteria such as bifidobacteria and lactic acid bacteria, and to ingest a high dietary fiber diet. For example, food materials related to the prevention and improvement of constipation include water-insoluble dietary fiber represented by wheat bran, water-soluble dietary fiber represented by indigestible dextrin, and digestion-resistant starch such as high amylose corn starch. It is known that the feces are excreted and the number of feces is increased, and the water content of feces is increased to soften feces and the like (for example, see Non-Patent Documents 1 to 4).
[0004]
However, in order for conventional food materials such as water-insoluble dietary fiber, water-soluble dietary fiber, and digestion-resistant starch to exhibit the above-mentioned physiological effects, they must be taken in high doses for a long period of time. Further, when foods and drinks are manufactured using them, it is often difficult to include a sufficient amount of the foods and drinks in foods because the original appearance, taste, texture, smoothness, and other textures are impaired. However, there have been problems that the application fields are limited, and that it is difficult to continue taking such foods and drinks for a long period of time.
[0005]
Hydroxypropylated starch is known to have high transparency, excellent film-forming properties, high storage stability at low temperatures, and high freeze / thaw stability. (For example, see Non-Patent Document 3).
However, it has not been known that hydroxypropylated starches have a constipation improving effect or an intestinal environment improving effect.
[0006]
An object of the present invention is to provide materials such as foods and pharmaceuticals that exhibit an effect of improving constipation and intestinal environment and the like, have high safety, have a wide application range, and have little loss of texture. .
[0007]
[Non-patent document 1]
Am J Gastroentero 1 1987 82 (12): 1259-63.
[Non-patent document 2]
Health and Nutrition Food Research 1999 Vol. 2 No. 1 p44
[Non-Patent Document 3]
Am J Clin Nutr 1995 62 (1): 121-30.
[Non-patent document 4]
Journal of the Japanese Association of Home Economics 1998 49 (9): 985-992
[0008]
[Means for Solving the Problems]
The present inventors have searched for a material that is different from dietary fiber typified by conventional indigestible starch, cellulose, and indigestible dextrin, and is effective in improving constipation and intestinal environment. A small amount of starch increases the amount of feces and its water content, increases short-chain fatty acids in the intestinal tract, lowers intestinal pH, and increases the expression of mucin in the intestinal tract with a small intake It has been found to be useful as a food or pharmaceutical material that has an effect of improving constipation and intestinal environment.
[0009]
That is, the present invention provides a constipation improving agent, an intestinal environment improving agent, an intestinal mucus production promoting agent, and an intestinal short chain fatty acid production promoting agent containing a hydroxypropylated starch as an active ingredient.
[0010]
BEST MODE FOR CARRYING OUT THE INVENTION
The hydroxypropylated starch of the present invention can be obtained by subjecting a starch or processed starch to hydroxypropylation by an ordinary method. Specifically, it can be obtained by reacting propylene oxide with starch.
In addition, National Frigex (from Tapioca, National Starch and Chemical Company), National 1658 (from corn, National Starch and Chemical Company), Thermflow (from Waxy Corn, National Starch and Chemical Company), Thermtex (from Waxy Corn, National Starch and Chemical Company) Commercial products such as Starch and Chemical Co., Ltd.) can also be used.
[0011]
Examples of the raw starch include waxy corn starch, corn starch, wheat starch, rice starch, glutinous rice starch, potato starch, sweet dew starch, tapioca starch, sago starch, and the like. The amylopectin content is 70% by weight or more, preferably 75% by weight. It is more preferable that the content is from 100% to 100%, more preferably from 90% to 100%, because the transparency of the size liquid is high, the appearance is not impaired when applied to foods and drinks, and the applicable range is widened. Of these, waxy corn starch and tapioca starch are preferred as the raw material starch.
[0012]
The “hydroxypropylated starch” in the present invention also includes a hydroxypropylated starch obtained by combining other processing. Examples of processing that can be combined include esterification of acetic acid, octenyl succinic acid, phosphoric acid, etc., etherification of carboxymethyl ether other than hydroxypropylation, trimetaphosphate, hexametaphosphate, phosphorus oxychloride, adipic acid , Epichlorohydrin, etc., a cross-linking treatment using a conventional cross-linking agent, an oxidation treatment, an acid treatment, a bleaching treatment, a wet heat treatment, a heat treatment, an enzyme treatment and the like. good. Among them, an esterification treatment is preferred, and a phosphorylation treatment, particularly a phosphoric acid crosslinking treatment, is preferred. As the degree of the phosphorylation treatment, the bound phosphorus content may be in the range of 0.0001 to 2%, preferably 0.0001 to 0.5%, more preferably 0.0001 to 0.2%. Is preferred from the viewpoint of texture and the like.
[0013]
As the degree of hydroxypropylation, the degree of substitution (the number of hydroxypropyl groups per anhydroglucose residue in starch) is preferably 0.001 to 1, more preferably 0.05 to 0.5. Yes, and more preferably 0.1 to 0.3.
[0014]
The hydroxypropylated starch can be produced from starch in a simple process with high purity and relatively low cost. In addition, it is highly safe and does not feel uncomfortable when used in various foods and drinks, pharmaceuticals, pet foods, and the like, as compared with conventional dietary fiber and indigestible starch. In addition, since it has excellent freezing resistance, it may have an advantage that deterioration due to thawing hardly occurs.
[0015]
The hydroxypropylated starch first has the effect of increasing the amount of feces and its water content and softening stool as shown in Examples described later, so that colon cancer with constipation as a risk factor is considered. And effects such as prevention of rectal cancer. Secondly, since it has the effect of increasing short-chain fatty acids in the intestinal tract and lowering intestinal pH, it prevents colon cancer and rectal cancer caused by deterioration of the intestinal environment, promotes calcium absorption, etc. Demonstrate the effect of. Third, since it has the effect of increasing the expression level of mucin in the intestinal tract, mucous protects the intestinal mucosa and can exert effects such as prevention of colitis, colon cancer and rectal cancer.
Therefore, the hydroxypropylated starch of the present invention can be used as a constipation improving agent, an intestinal environment improving agent, an intestinal mucus production promoting agent, an intestinal short-chain fatty acid production promoting agent (hereinafter referred to as a constipation improving agent or the like). It can be a food or pharmaceutical material for animals.
[0016]
The constipation improving agent and the like of the present invention can be administered alone to humans and animals by one or more of hydroxypropylated starch, and can also be incorporated in various foods and drinks, pharmaceuticals, pet foods and the like. As foods, it can be applied to beauty foods, foods for the sick, and foods for specific health, which are based on physiological functions such as improvement of constipation, improvement of intestinal environment, promotion of Ca absorption, and protection of gastrointestinal mucosa. When used as pharmaceuticals, for example, oral solid preparations such as tablets and granules, and oral liquid preparations such as internal liquids and syrups can be prepared.
When preparing an oral solid preparation, an excipient and, if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent, a flavoring agent, etc. are added to the hydroxypropylated starch of the present invention. After that, tablets, coated tablets, granules, powders, capsules and the like can be produced by a conventional method. In the case of preparing a liquid preparation for oral use, a flavoring agent, a buffer, a stabilizing agent, a flavoring agent and the like can be added, and an internal liquid solution, a syrup, an elixir and the like can be produced by a conventional method.
[0017]
The amount of the hydroxypropylated starch to be blended in each of the above-mentioned preparations is usually 5 to 100% by weight, preferably 20 to 100% by weight, and more preferably 30 to 100% by weight.
[0018]
The dose (effective intake) of the constipation improving agent or the like of the present invention is preferably 0.01 g / kg body weight or more per day, particularly 0.1 g / kg body weight or more, and more preferably 0.4 g / kg body weight or more. Is preferred.
[0019]
【Example】
[0020]
Test Example 1 Constipation improving effect, intestinal environment improving effect, intestinal mucus production promoting effect Corn starch was obtained from National Starch and Chemical Company. As hydroxypropylated starches, commercially available National 1658 (derived from corn, National Starch and Chemical Co., Ltd.), Thermflow (derived from waxy corn, National Starch and Chemical Co., Ltd.), and the above-mentioned corn starch as J Nutr 1998 128 (5 ): Hydroxypropylated by the method described in 848-54 was used.
[0021]
A group of five SD rats (male, 8 weeks old) was bred for 1 week using various starches and a diet prepared according to the formulation shown in Table 1. During this period, the fecal dry weight and moisture content were measured daily. After breeding, the rats were sacrificed, and the pH of the cecal contents and the amount of short-chain fatty acids (total amount of acetic acid, propionic acid, and butyric acid) were measured. Further, the rat colon was excised and the expression of mucin gene (MUC3) was quantified by Northern blotting.
The pH was measured with a pH meter after diluting the cecal contents twice with distilled water, and the short-chain fatty acids were diluted with the cecal contents ten times with 0.05N H 2 SO 4 and then HPLC (eluent: 0). .12N sulfuric acid column: quantified at IC sep TCE-10N 300 (Tonrath Genosic) at a flow rate of 0.4 mL / min.
Table 2 shows the fecal excretion amount, the average fecal water content, the cecal pH, the amount of short-chain fatty acid in the cecum, and the mucin expression amount (relative amount with respect to corn starch of 100) in rats.
[0022]
[Table 1]
Figure 2004315405
[0023]
[Table 2]
Figure 2004315405
[0024]
From the results in Table 2, the rats fed the diet containing 5% of the hydroxypropylated starch (derived from corn and waxy corn), compared to the mice fed the diet containing the raw starch (corn starch), It can be seen that the amount of feces is large, the water content of feces is high, and the effect of improving constipation is observed. In addition, since the concentration of the short-chain fatty acid in the cecum is high, the pH in the cecum is low, which indicates that the effect of improving the intestinal environment is recognized. Further, the expression level of mucin (MUC3) was large, indicating that the intestinal mucus production promoting effect was observed.
[0025]
【The invention's effect】
The constipation-improving agent of the present invention has effects of improving constipation, promoting the production of intestinal short-chain fatty acids, improving the intestinal environment such as intestinal pH, and promoting intestinal mucus production, and is useful as foods, pharmaceuticals, and the like. . In particular, hydroxypropylated starch or a derivative thereof, which is an active ingredient, is excellent in safety to the human body because of using starch as a raw material, and is easily gelatinized, so that the range of application to foods and beverages is wide, bread, noodles, baked confectionery (Cakes, cookies, etc.), jellies, beverages, etc., they rarely impair the original texture. Further, since it has excellent freezing resistance and is hardly deteriorated even when thawed, it is highly useful when used as various foods and drinks.

Claims (4)

ヒドロキシプロピル化された澱粉を有効成分とする便秘改善剤。A constipation improving agent comprising hydroxypropylated starch as an active ingredient. ヒドロキシプロピル化された澱粉を有効成分とする腸内環境改善剤。An intestinal environment improving agent containing hydroxypropylated starch as an active ingredient. ヒドロキシプロピル化された澱粉を有効成分とする腸管粘液産生促進剤。An intestinal mucus production promoter comprising a hydroxypropylated starch as an active ingredient. ヒドロキシプロピル化された澱粉を有効成分とする腸内短鎖脂肪酸産生促進剤。An intestinal short-chain fatty acid production promoter comprising hydroxypropylated starch as an active ingredient.
JP2003109959A 2003-04-15 2003-04-15 Constipation improving agent Expired - Fee Related JP4463494B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003109959A JP4463494B2 (en) 2003-04-15 2003-04-15 Constipation improving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003109959A JP4463494B2 (en) 2003-04-15 2003-04-15 Constipation improving agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009267775A Division JP2010047606A (en) 2009-11-25 2009-11-25 Constipation dissolving agent

Publications (2)

Publication Number Publication Date
JP2004315405A true JP2004315405A (en) 2004-11-11
JP4463494B2 JP4463494B2 (en) 2010-05-19

Family

ID=33470944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003109959A Expired - Fee Related JP4463494B2 (en) 2003-04-15 2003-04-15 Constipation improving agent

Country Status (1)

Country Link
JP (1) JP4463494B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006342085A (en) * 2005-06-08 2006-12-21 Kao Corp Gip secretion inhibitor
JP2008013460A (en) * 2006-07-04 2008-01-24 Kao Corp Improver for endurance
JP2011236239A (en) * 2011-07-27 2011-11-24 Kao Corp Gip secretion inhibitor
JP2012246310A (en) * 2012-08-31 2012-12-13 Kao Corp Improver for endurance

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006342085A (en) * 2005-06-08 2006-12-21 Kao Corp Gip secretion inhibitor
JP2008013460A (en) * 2006-07-04 2008-01-24 Kao Corp Improver for endurance
JP2011236239A (en) * 2011-07-27 2011-11-24 Kao Corp Gip secretion inhibitor
JP2012246310A (en) * 2012-08-31 2012-12-13 Kao Corp Improver for endurance

Also Published As

Publication number Publication date
JP4463494B2 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
JP5026657B2 (en) Obesity prevention / amelioration agent
JP2006342085A (en) Gip secretion inhibitor
CA2578952C (en) Waxy corn starch and use thereof for treating obesity and diabetes
US20090275530A1 (en) Gastric Raft Composition Comprising Preferably Processed Starches For Inducing Satiety
JP2006508916A (en) Branched alpha-glucan for weight management
JP5581129B2 (en) Obesity prevention / amelioration agent
AU2005280994B2 (en) Agent for preventing and ameliorating obesity
JP4463494B2 (en) Constipation improving agent
JP7091344B2 (en) Prebiotic dietary supplements to promote amylose-degrading activity and activity of short-chain fatty acid-producing microorganisms
US9421219B2 (en) Methods and compositions for preventing allergy and infection
JP2010047606A (en) Constipation dissolving agent
JP2021184704A (en) Grain-like granular food
JP2922504B1 (en) Thickening composition for assisting swallowing and taking of water, food and medicine
JP2010053138A (en) Obesity-preventing/improving agent
JP5555291B2 (en) Endurance improver
JP2017095403A (en) Triglyceride-lowering drugs, body weight-suppressing drugs, excretion-increasing drugs, foods and drinks, feed and medicines
JP5490350B2 (en) Endurance improver
JP2003339352A (en) Anti-inflammatory and chemoprophylactic composition
JP2011236239A (en) Gip secretion inhibitor
JP2011037715A (en) Body weight variation inhibitor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090721

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090825

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100217

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130226

Year of fee payment: 3

R151 Written notification of patent or utility model registration

Ref document number: 4463494

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140226

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees